Back to Search
Start Over
Comprehensive evaluation of intravitreal conbercept versus half-dose photodynamic therapy for chronic central serous chorioretinopathy
- Source :
- Int J Ophthalmol, International Journal of Ophthalmology, Vol 14, Iss 5, Pp 719-724 (2021)
- Publication Year :
- 2021
- Publisher :
- International Journal of Ophthalmology Press, 2021.
-
Abstract
- AIM: To compare the safety and efficacy of conbercept intravitreal injection and half-dose photodynamic therapy (PDT) in treating chronic central serous chorioretinopathy (CSC). METHODS: This study was retrospective. Thirty-seven patients (37 eyes) with chronic CSC received conbercept injections while 57 patients (57 eyes) were treated with half-dose PDT. All subjects were followed in 6mo. Outcome measures included change in best-corrected visual acuity (BCVA), central macular thickness (CMT), subfoveal choroidal thickness (SFCT), and resolution of subretinal fluid (SRF). RESULTS: There was no adverse event observed in either treatment group. At the 6-month follow-up, 26 eyes (70.3%) in the conbercept group and 54 eyes (94.7%) in the half-dose PDT group (P0.05). The SFCT also improved in all subjects (P
- Subjects :
- medicine.medical_specialty
Visual acuity
genetic structures
medicine.medical_treatment
Photodynamic therapy
subfoveal choroidal thickness
Chronic central serous chorioretinopathy
Conbercept
03 medical and health sciences
0302 clinical medicine
Clinical Research
Ophthalmology
medicine
Adverse effect
central serous chorioretinopathy
business.industry
Outcome measures
RE1-994
eye diseases
photodynamic therapy
Initial phase
030221 ophthalmology & optometry
sense organs
Subretinal fluid
medicine.symptom
business
conbercept
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- Int J Ophthalmol, International Journal of Ophthalmology, Vol 14, Iss 5, Pp 719-724 (2021)
- Accession number :
- edsair.doi.dedup.....baab24d0b8fb237df9d684d62b27e255